Ranolazine in the prevention of anthracycline cardiotoxicity

Pharmacological Research

Volumn 79, Issue , 2014, Pages 88-102

  Corradi, Francesco ^a   Paolini, Luca ^a   De Caterina, Raffaele ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

Anthracyclines; Cardiotoxicity; Heart failure; Oxidative stress; Reactive oxygen species

Indexed keywords

ACLARUBICIN; ADENOSINE TRIPHOSPHATE; ALCOHOL; AMRUBICIN; ANTHRACYCLINE DERIVATIVE; CALCIUM ION; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IDARUBICIN; IRON COMPLEX; RANOLAZINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SODIUM ION; SUPEROXIDE;

ALCOHOL METABOLISM; APOPTOSIS; BIOGENESIS; CALCIUM CELL LEVEL; CARDIOTOXICITY; CELL DEATH; CHEMICAL REACTION; CLINICAL FEATURE; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DRUG MECHANISM; DRUG STRUCTURE; ENERGY TRANSFER; FATTY ACID OXIDATION; FENTON REACTION; HEART FAILURE; HEART MUSCLE; HEART PROTECTION; HOMEOSTASIS; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANTHRACYCLINES; CARDIOTOXICITY; HEART FAILURE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

ACETANILIDES; ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; HEART DISEASES; HUMANS; PIPERAZINES; SODIUM CHANNEL BLOCKERS;

EID: 84890071245     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.11.001     Document Type: Review

References (147)

1. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229 (Pubitemid 38720829)
2. M.S. Ewer, and S.M. Ewer Cardiotoxicity of anticancer treatments: what the cardiologist needs to know Nat Rev Cardiol 7 2010 564 575
3. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900 905 (Pubitemid 28446849)
4. P. Menna, O.G. Paz, M. Chello, E. Covino, E. Salvatorelli, and G. Minotti Anthracycline cardiotoxicity Expert Opin Drug Saf 11 Suppl. 1 2012 S21 S36
5. T. Eschenhagen, T. Force, M.S. Ewer, G.W. de Keulenaer, T.M. Suter, and S.D. Anker Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
6. P. Perego, E. Corna, M. De Cesare, L. Gatti, D. Polizzi, and G. Pratesi Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines Curr Med Chem 8 2001 31 37
7. L.M. Buja, and D. Vela Cardiomyocyte death and renewal in the normal and diseased heart Cardiovasc Pathol 17 2008 349 374
8. T. Simunek, M. Sterba, O. Popelova, M. Adamcova, R. Hrdina, and V. Gersl Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol Rep 61 2009 154 171
9. M. Stěrba, O. Popelová, A. Vávrová, E. Jirkovský, P. Kovaříková, V. Geršl, and T. Simůnek Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection Antioxid Redox Signal 18 8 2013 March 10 899 929 http://www.ncbi.nlm.nih.gov/pubmed/22794198
10. Y. Octavia, C.G. Tocchetti, K.L. Gabrielson, S. Janssens, H.J. Crijns, and A.L. Moens Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies J Mol Cell Cardiol 52 2012 1213 1225
11. S. Sossalla, and L.S. Maier Role of ranolazine in angina, heart failure, arrhythmias, and diabetes Pharmacol Ther 133 2012 311 323
12. M. Kohlhaas, and C. Maack Interplay of defective excitation-contraction coupling, energy starvation, and oxidative stress in heart failure Trends Cardiovasc Med 21 2011 69 73
13. R.E. Scully, and S.E. Lipshultz Anthracycline cardiotoxicity in long-term survivors of childhood cancer Cardiovasc Toxicol 7 2007 122 128 (Pubitemid 47339858)
14. B.M. Aleman, A.W. van den Belt-Dusebout, M.L. De Bruin, M.B. van't Veer, M.H. Baaijens, and J.P. de Boer Late cardiotoxicity after treatment for hodgkin lymphoma Blood 109 2007 1878 1886 (Pubitemid 46348183)
15. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis Jr., A.L. Von Hoff, and M. Rozencweig Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717 (Pubitemid 10218041)
16. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879 (Pubitemid 36605157)
17. J.G. Blanco, C.L. Sun, W. Landier, L. Chen, D. Esparza-Duran, and W. Leisenring Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - a report from the children's oncology group J Clin Oncol 30 2012 1415 1421
18. S.E. Lipshultz, S.R. Lipsitz, S.E. Sallan, V.M. Dalton, S.M. Mone, and R.D. Gelber Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia J Clin Oncol 23 2005 2629 2636 (Pubitemid 46179451)
19. E. Barry, J.A. Alvarez, R.E. Scully, T.L. Miller, and S.E. Lipshultz Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management Expert Opin Pharmacother 8 2007 1039 1058 (Pubitemid 46929299)
20. B.H. Trachtenberg, D.C. Landy, V.I. Franco, J.M. Henkel, E.J. Pearson, and T.L. Miller Anthracycline-associated cardiotoxicity in survivors of childhood cancer Pediatr Cardiol 32 2011 342 353
21. G. Minotti Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs J Pharmacol Exp Ther 346 2013 343 349
22. S. Zhang, X. Liu, T. Bawa-Khalfe, L.S. Lu, Y.L. Lyu, and L.F. Liu Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 18 2012 1639 1642
23. J.H. Doroshow, and K.J. Davies Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical J Biol Chem 261 1986 3068 3074 (Pubitemid 17204910)
24. R.D. Olson, and P.S. Mushlin Doxorubicin cardiotoxicity: analysis of prevailing hypotheses FASEB J 4 1990 3076 3086
25. X. Xu, H.L. Persson, and D.R. Richardson Molecular pharmacology of the interaction of anthracyclines with iron Mol Pharmacol 68 2005 261 271 (Pubitemid 41058288)
26. B. Kalyanaraman, J. Joseph, S. Kalivendi, S. Wang, E. Konorev, and S. Kotamraju Doxorubicin-induced apoptosis: implications in cardiotoxicity Mol Cell Biochem 234-235 2002 119 124 (Pubitemid 34777848)
27. Y.J. Kang, Y. Chen, and P.N. Epstein Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice J Biol Chem 271 1996 12610 12616 (Pubitemid 26160936)
28. H.C. Yen, T.D. Oberley, S. Vichitbandha, Y.S. Ho, and D.K. St Clair The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice J Clin Invest 98 1996 1253 1260 (Pubitemid 26299939)
29. Y. Xiong, X. Liu, C.P. Lee, B.H. Chua, and Y.S. Ho Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase Free Radic Biol Med 41 2006 46 55 (Pubitemid 43866460)
30. K. Bedard, and K.H. Krause The nox family of ros-generating nadph oxidases: physiology and pathophysiology Physiol Rev 87 2007 245 313 (Pubitemid 46209993)
31. B. Lassegue, A. San Martin, and K.K. Griendling Biochemistry, physiology, and pathophysiology of nadph oxidases in the cardiovascular system Circ Res 110 2012 1364 1390
32. Y. Zhao, D. McLaughlin, E. Robinson, A.P. Harvey, M.B. Hookham, and A.M. Shah Nox2 nadph oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy Cancer Res 70 2010 9287 9297
33. Y. Octavia, H.P. Brunner-La Rocca, and A.L. Moens Nadph oxidase-dependent oxidative stress in the failing heart: from pathogenic roles to therapeutic approach Free Radic Biol Med 52 2012 291 297
34. D.E. Handy, and J. Loscalzo Redox regulation of mitochondrial function Antioxid Redox Signal 16 2012 1323 1367
35. J.F. Turrens Mitochondrial formation of reactive oxygen species J Physiol 552 2003 335 344 (Pubitemid 37321833)
36. M.P. Murphy How mitochondria produce reactive oxygen species Biochem J 417 2009 1 13
37. M. Tokarska-Schlattner, M. Zaugg, C. Zuppinger, T. Wallimann, and U. Schlattner New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics J Mol Cell Cardiol 41 2006 389 405 (Pubitemid 44362995)
38. A.V. Pointon, T.M. Walker, K.M. Phillips, J. Luo, J. Riley, and S.D. Zhang Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to atp loss and caspase 3 activation PLoS One 5 2010 e12733
39. M.Y. Maslov, V.P. Chacko, G.A. Hirsch, A. Akki, M.K. Leppo, and C. Steenbergen Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction Am J Physiol Heart Circ Physiol 299 2010 H332 H337
40. M. Kohlhaas, T. Liu, A. Knopp, T. Zeller, M.F. Ong, and M. Bohm Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes Circulation 121 2010 1606 1613
41. L. Gianni, E.H. Herman, S.E. Lipshultz, G. Minotti, N. Sarvazyan, and D.B. Sawyer Anthracycline cardiotoxicity: from bench to bedside J Clin Oncol 26 2008 3777 3784
42. K. Sugamura, and J.F. Keaney Jr. Reactive oxygen species in cardiovascular disease Free Radic Biol Med 51 2011 978 992
43. M.P. Sumandea, and S.F. Steinberg Redox signaling and cardiac sarcomeres J Biol Chem 286 2011 9921 9927
44. H. Tsutsui, S. Kinugawa, and S. Matsushima Oxidative stress and heart failure Am J Physiol Heart Circ Physiol 301 2011 H2181 H2190
45. D. Shao, S. Oka, C.D. Brady, J. Haendeler, P. Eaton, and J. Sadoshima Redox modification of cell signaling in the cardiovascular system J Mol Cell Cardiol 52 2012 550 558
46. S.F. Steinberg Oxidative stress and sarcomeric proteins Circ Res 112 2013 393 405
47. T. L'Ecuyer, S. Sanjeev, R. Thomas, R. Novak, L. Das, and W. Campbell DNA damage is an early event in doxorubicin-induced cardiac myocyte death Am J Physiol Heart Circ Physiol 291 2006 H1273 H1280
48. J. Liu, W. Mao, B. Ding, and C.S. Liang Erks/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in h9c2 cells and cardiomyocytes Am J Physiol Heart Circ Physiol 295 2008 H1956 H1965
49. S. Gratia, L. Kay, L. Potenza, A. Seffouh, V. Novel-Chate, and C. Schnebelen Inhibition of ampk signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress Cardiovasc Res 95 2012 290 299
50. G.L. Forrest, B. Gonzalez, W. Tseng, X. Li, and J. Mann Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice Cancer Res 60 2000 5158 5164
51. J.G. Blanco, W.M. Leisenring, V.M. Gonzalez-Covarrubias, T.I. Kawashima, S.M. Davies, and M.V. Relling Genetic polymorphisms in the carbonyl reductase 3 gene cbr3 and the Nad(P)H: quinone oxidoreductase 1 gene nqo1 in patients who developed anthracycline-related congestive heart failure after childhood cancer Cancer 112 2008 2789 2795 (Pubitemid 351969225)
52. C.J. McLeod, I. Pagel, and M.N. Sack The mitochondrial biogenesis regulatory program in cardiac adaptation to ischemia - a putative target for therapeutic intervention Trends Cardiovasc Med 15 2005 118 123 (Pubitemid 41021736)
53. D.P. Kelly, and R.C. Scarpulla Transcriptional regulatory circuits controlling mitochondrial biogenesis and function Genes Dev 18 2004 357 368 (Pubitemid 38316342)
54. T.C. Leone, and D.P. Kelly Transcriptional control of cardiac fuel metabolism and mitochondrial function Cold Spring Harb Symp Quant Biol 76 2011 175 182
55. H.B. Suliman, M.S. Carraway, A.S. Ali, C.M. Reynolds, K.E. Welty-Wolf, and C.A. Piantadosi The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy J Clin Invest 117 2007 3730 3741 (Pubitemid 350224084)
56. K. Miyagawa, N. Emoto, B. Widyantoro, K. Nakayama, K. Yagi, and Y. Rikitake Attenuation of doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment Hypertension 55 2010 738 746
57. R.C. Scarpulla Metabolic control of mitochondrial biogenesis through the pgc-1 family regulatory network Biochim Biophys Acta 1813 2011 1269 1278
58. E. Jirkovsky, O. Popelova, P. Krivakova-Stankova, A. Vavrova, M. Hroch, and P. Haskova Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways J Pharmacol Exp Ther 343 2012 468 478
59. O. Marcillat, Y. Zhang, and K.J. Davies Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin Biochem J 259 1989 181 189 (Pubitemid 19100513)
60. S.N. Kumar, E.A. Konorev, D. Aggarwal, and B. Kalyanaraman Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte J Proteomics 74 2011 683 697
61. C.A. Piantadosi, M.S. Carraway, A. Babiker, and H.B. Suliman Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via nrf2-mediated transcriptional control of nuclear respiratory factor-1 Circ Res 103 2008 1232 1240
62. K. Ohkura, J.D. Lee, H. Shimizu, A. Nakano, H. Uzui, and M. Horikoshi Mitochondrials complex i activity is reduced in latent adriamycin-induced cardiomyopathy of rat Mol Cell Biochem 248 2003 203 208 (Pubitemid 36833661)
63. J.M. Berthiaume, and K.B. Wallace Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment Cardiovasc Toxicol 7 2007 178 191 (Pubitemid 47575003)
64. M. Sterba, O. Popelova, J. Lenco, A. Fucikova, E. Brcakova, and Y. Mazurova Proteomic insights into chronic anthracycline cardiotoxicity J Mol Cell Cardiol 50 2011 849 862
65. K.E. Merten, W. Feng, L. Zhang, W. Pierce, J. Cai, and J.B. Klein Modulation of cytochrome c oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity J Pharmacol Exp Ther 315 2005 1314 1319 (Pubitemid 41635420)
66. S. Gratia, L. Kay, S. Michelland, M. Seve, U. Schlattner, and M. Tokarska-Schlattner Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity J Proteomics 75 2012 4705 4716
67. R.A. Carvalho, R.P. Sousa, V.J. Cadete, G.D. Lopaschuk, C.M. Palmeira, and J.A. Bjork Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy Toxicology 270 2010 92 98
68. O.J. Arola, A. Saraste, K. Pulkki, M. Kallajoki, M. Parvinen, and L.M. Voipio-Pulkki Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis Cancer Res 60 2000 1789 1792 (Pubitemid 30207630)
69. J. Shi, L. Zhang, Y.W. Zhang, M. Surma, R. Mark Payne, and L. Wei Downregulation of doxorubicin-induced myocardial apoptosis accompanies postnatal heart maturation Am J Physiol Heart Circ Physiol 302 2012 H1603 H1613
70. Y.W. Zhang, J. Shi, Y.J. Li, and L. Wei Cardiomyocyte death in doxorubicin-induced cardiotoxicity Arch Immunol Ther Exp (Warsz) 57 2009 435 445
71. D.B. Sawyer, X. Peng, B. Chen, L. Pentassuglia, and C.C. Lim Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53 2010 105 113
72. J. Shi, E. Abdelwahid, and L. Wei Apoptosis in anthracycline cardiomyopathy Curr Pediatr Rev 7 2011 329 336
73. D. Montaigne, C. Hurt, and R. Neviere Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies Biochem Res Int 2012 2012 951539
74. D.V. Unverferth, R.D. Magorien, B.P. Unverferth, R.L. Talley, S.P. Balcerzak, and N. Baba Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration Cancer Treat Rep 65 1981 1093 1097 (Pubitemid 12237742)
75. R.A. Rowan, M.A. Masek, and M.E. Billingham Ultrastructural morphometric analysis of endomyocardial biopsies. Idiopathic dilated cardiomyopathy, anthracycline cardiotoxicity, and normal myocardium Am J Cardiovasc Pathol 2 1988 137 144
76. A.C. Childs, S.L. Phaneuf, A.J. Dirks, T. Phillips, and C. Leeuwenburgh Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and bcl-2:Bax ratio Cancer Res 62 2002 4592 4598
77. J. Ma, Y. Wang, D. Zheng, M. Wei, H. Xu, and T. Peng Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways Cardiovasc Res 97 2013 77 87
78. J. Yang, B. Maity, J. Huang, Z. Gao, A. Stewart, and R.M. Weiss G-protein inactivator rgs6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin Cancer Res 73 2013 1662 1667
79. Y.L. Lyu, J.E. Kerrigan, C.P. Lin, A.M. Azarova, Y.C. Tsai, and Y. Ban Topoisomerase iibeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res 67 2007 8839 8846 (Pubitemid 47437460)
80. E.A. Konorev, S. Vanamala, and B. Kalyanaraman Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes Free Radic Biol Med 45 2008 1723 1728
81. S. Miyata, G. Takemura, K. Kosai, T. Takahashi, M. Esaki, and L. Li Anti-fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis Am J Pathol 176 2010 687 698
82. E. Piegari, A. De Angelis, D. Cappetta, R. Russo, G. Esposito, and S. Costantino Doxorubicin induces senescence and impairs function of human cardiac progenitor cells Basic Res Cardiol 108 2013 334
83. M. Arai, A. Yoguchi, T. Takizawa, T. Yokoyama, T. Kanda, and M. Kurabayashi Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum ca(2+)-atpase gene transcription Circ Res 86 2000 8 14 (Pubitemid 30044162)
84. K. Saeki, I. Obi, N. Ogiku, M. Shigekawa, T. Imagawa, and T. Matsumoto Doxorubicin directly binds to the cardiac-type ryanodine receptor Life Sci 70 2002 2377 2389 (Pubitemid 34261048)
85. S.Y. Kim, S.J. Kim, B.J. Kim, S.Y. Rah, S.M. Chung, and M.J. Im Doxorubicin-induced reactive oxygen species generation and intracellular ca2+ increase are reciprocally modulated in rat cardiomyocytes Exp Mol Med 38 2006 535 545
86. Y.M. Jang, S. Kendaiah, B. Drew, T. Phillips, C. Selman, and D. Julian Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats FEBS Lett 577 2004 483 490 (Pubitemid 39539206)
87. C.C. Lim, C. Zuppinger, X. Guo, G.M. Kuster, M. Helmes, and H.M. Eppenberger Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes J Biol Chem 279 2004 8290 8299 (Pubitemid 38294721)
88. E.C. Campos, J.L. O'Connell, L.M. Malvestio, M.M. Romano, S.G. Ramos, and M.R. Celes Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy Eur J Pharmacol 670 2011 541 553
89. K.B. Wallace Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis Cardiovasc Toxicol 7 2007 101 107 (Pubitemid 47339855)
90. P.M. Sokolove, and R.G. Shinaberry Na+-independent release of ca2+ from rat heart mitochondria. Induction by adriamycin aglycone Biochem Pharmacol 37 1988 803 812 (Pubitemid 18058449)
91. S. Zhou, A. Starkov, M.K. Froberg, R.L. Leino, and K.B. Wallace Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin Cancer Res 61 2001 771 777 (Pubitemid 32128645)
92. S. Zhou, C.M. Palmeira, and K.B. Wallace Doxorubicin-induced persistent oxidative stress to cardiac myocytes Toxicol Lett 121 2001 151 157 (Pubitemid 32441771)
93. V.G. Zaha, and L.H. Young Amp-activated protein kinase regulation and biological actions in the heart Circ Res 111 2012 800 814
94. M. Harada, S.N. Nattel, and S. Nattel Amp-activated protein kinase: potential role in cardiac electrophysiology and arrhythmias Circ Arrhythm Electrophysiol 5 2012 860 867
95. S. Wang, P. Song, and M.H. Zou Amp-activated protein kinase, stress responses and cardiovascular diseases Clin Sci (Lond) 122 2012 555 573
96. J. Nagendran, T.J. Waller, and J.R. Dyck Ampk signalling and the control of substrate use in the heart Mol Cell Endocrinol 366 2013 180 193
97. R.L. Hurley, L.K. Barre, S.D. Wood, K.A. Anderson, B.E. Kemp, and A.R. Means Regulation of amp-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular camp J Biol Chem 281 2006 36662 36672 (Pubitemid 46042133)
98. M.J. Sanders, P.O. Grondin, B.D. Hegarty, M.A. Snowden, and D. Carling Investigating the mechanism for amp activation of the amp-activated protein kinase cascade Biochem J 403 2007 139 148 (Pubitemid 46569875)
99. D.G. Hardie Amp-activated protein kinase: an energy sensor that regulates all aspects of cell function Genes Dev 25 2011 1895 1908
100. N. Kudo, A.J. Barr, R.L. Barr, S. Desai, and G.D. Lopaschuk High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-coa levels due to an increase in 5'-amp-activated protein kinase inhibition of acetyl-coa carboxylase J Biol Chem 270 1995 17513 17520
101. C. Canto, Z. Gerhart-Hines, J.N. Feige, M. Lagouge, L. Noriega, and J.C. Milne AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity Nature 458 2009 1056 1060
102. M. Tokarska-Schlattner, M. Zaugg, R. da Silva, E. Lucchinetti, M.C. Schaub, and T. Wallimann Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply Am J Physiol Heart Circ Physiol 289 2005 H37 H47
103. S. Wang, P. Song, and M.H. Zou Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1 J Biol Chem 287 2012 8001 8012
104. B. Sid, J. Verrax, and P.B. Calderon Role of ampk activation in oxidative cell damage: implications for alcohol-induced liver disease Biochem Pharmacol 86 2013 200 209
105. P. Song, and M.H. Zou Regulation of Nad(P)H oxidases by ampk in cardiovascular systems Free Radic Biol Med 52 2012 1607 1619
106. T. Wenz Regulation of mitochondrial biogenesis and PGC-1alpha under cellular stress Mitochondrion 13 2013 134 142
107. H.M. O'Neill, G.P. Holloway, and G.R. Steinberg AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity Mol Cell Endocrinol 366 2013 135 151
108. D. Cesselli, I. Jakoniuk, L. Barlucchi, A.P. Beltrami, T.H. Hintze, and B. Nadal-Ginard Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy Circ Res 89 2001 279 286 (Pubitemid 34132687)
109. V.P. van Empel, A.T. Bertrand, L. Hofstra, H.J. Crijns, P.A. Doevendans, and L.J. De Windt Myocyte apoptosis in heart failure Cardiovasc Res 67 2005 21 29 (Pubitemid 40798289)
110. A. De Angelis, E. Piegari, D. Cappetta, L. Marino, A. Filippelli, and L. Berrino Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function Circulation 121 2010 276 292
111. A. Saraste, K. Pulkki, M. Kallajoki, P. Heikkila, P. Laine, and S. Mattila Cardiomyocyte apoptosis and progression of heart failure to transplantation Eur J Clin Invest 29 1999 380 386 (Pubitemid 29209759)
112. R.S. Whelan, V. Kaplinskiy, and R.N. Kitsis Cell death in the pathogenesis of heart disease: mechanisms and significance Annu Rev Physiol 72 2010 19 44
113. G. Olivetti, R. Abbi, F. Quaini, J. Kajstura, W. Cheng, and J.A. Nitahara Apoptosis in the failing human heart N Engl J Med 336 1997 1131 1141
114. N.B. Rayment, A.J. Haven, B. Madden, A. Murday, R. Trickey, and M. Shipley Myocyte loss in chronic heart failure J Pathol 188 1999 213 219 (Pubitemid 29253943)
115. M. Chiong, Z.V. Wang, Z. Pedrozo, D.J. Cao, R. Troncoso, and M. Ibacache Cardiomyocyte death: mechanisms and translational implications Cell Death Dis 2 2011 e244
116. D. Wencker, M. Chandra, K. Nguyen, W. Miao, S. Garantziotis, and S.M. Factor A mechanistic role for cardiac myocyte apoptosis in heart failure J Clin Invest 111 2003 1497 1504 (Pubitemid 38063282)
117. C. Huang, X. Zhang, J.M. Ramil, S. Rikka, L. Kim, and Y. Lee Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice Circulation 121 2010 675 683
118. C.M. Sag, S. Wagner, and L.S. Maier Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes Free Radic Biol Med 63 2013 338 349
119. S. Wagner, A.G. Rokita, M.E. Anderson, and L.S. Maier Redox regulation of sodium and calcium handling Antioxid Redox Signal 18 2013 1063 1077
120. J. Bay, M. Kohlhaas, and C. Maack Intracellular Na(+) and cardiac metabolism J Mol Cell Cardiol 61 2013 20 27
121. Y. Song, J.C. Shryock, S. Wagner, L.S. Maier, and L. Belardinelli Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction J Pharmacol Exp Ther 318 2006 214 222
122. J.R. Erickson, B.J. He, I.M. Grumbach, and M.E. Anderson Camkii in the cardiovascular system: sensing redox states Physiol Rev 91 2011 889 915
123. N. Morita, J.H. Lee, Y. Xie, A. Sovari, Z. Qu, and J.N. Weiss Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine J Am Coll Cardiol 57 2011 366 375
124. J.D. Lovelock, M.M. Monasky, E.M. Jeong, H.A. Lardin, H. Liu, and B.G. Patel Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity Circ Res 110 2012 841 850
125. S. Wagner, H.M. Ruff, S.L. Weber, S. Bellmann, T. Sowa, and T. Schulte Reactive oxygen species-activated ca/calmodulin kinase IIdelta is required for late i(na) augmentation leading to cellular Na and Ca overload Circ Res 108 2011 555 565
126. N.M. Ashpole, A.W. Herren, K.S. Ginsburg, J.D. Brogan, D.E. Johnson, and T.R. Cummins Ca2+/calmodulin-dependent protein kinase ii (camkii) regulates cardiac sodium channel nav1.5 gating by multiple phosphorylation sites J Biol Chem 287 2012 19856 19869
127. E. Murphy, and D.A. Eisner Regulation of intracellular and mitochondrial sodium in health and disease Circ Res 104 2009 292 303
128. M. Kohlhaas, and C. Maack Adverse bioenergetic consequences of Na+-Ca2+ exchanger-mediated Ca2+ influx in cardiac myocytes Circulation 122 2010 2273 2280
129. C.M. Sag, A.C. Kohler, M.E. Anderson, J. Backs, and L.S. Maier CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes J Mol Cell Cardiol 51 2011 749 759
130. M. Patron, A. Raffaello, V. Granatiero, A. Tosatto, G. Merli, and D. De Stefani The mitochondrial calcium uniporter (MCU): molecular identity and physiological roles J Biol Chem 288 2013 10750 10758
131. C. Maack, S. Cortassa, M.A. Aon, A.N. Ganesan, T. Liu, and B. O'Rourke Elevated cytosolic NA+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes Circ Res 99 2006 172 182 (Pubitemid 44297041)
132. T. Liu, and B. O'Rourke Regulation of mitochondrial Ca2+ and its effects on energetics and redox balance in normal and failing heart J Bioenerg Biomembr 41 2009 127 132
133. E.V. Kalinina, N.N. Chernov, and A.N. Saprin Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes Biochemistry (Mosc) 73 2008 1493 1510
134. W. Ying NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences Antioxid Redox Signal 10 2008 179 206
135. S. Sossalla, S. Wagner, E.C. Rasenack, H. Ruff, S.L. Weber, and F.A. Schondube Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - role of late sodium current and intracellular ion accumulation J Mol Cell Cardiol 45 2008 32 43
136. J.C. Shryock, and L. Belardinelli Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium Br J Pharmacol 153 2008 1128 1132 (Pubitemid 351415493)
137. M.R. Gralinski, S.C. Black, K.S. Kilgore, A.Y. Chou, J.G. McCormack, and B.R. Lucchesi Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart Cardiovasc Res 28 1994 1231 1237 (Pubitemid 24264731)
138. V.M. Figueredo, G.S. Pressman, A. Romero-Corral, E. Murdock, P. Holderbach, and D.L. Morris Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina J Cardiovasc Pharmacol Ther 16 2011 168 172
139. B.R. Chaitman, S.L. Skettino, J.O. Parker, P. Hanley, J. Meluzin, and J. Kuch Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J Am Coll Cardiol 43 2004 1375 1382 (Pubitemid 38496341)
140. P.H. Stone, N.A. Gratsiansky, A. Blokhin, I.Z. Huang, and L. Meng Antianginal efficacy of ranolazine when added to treatment with amlodipine: the erica (efficacy of ranolazine in chronic angina) trial J Am Coll Cardiol 48 2006 566 575 (Pubitemid 44093970)
141. D.A. Morrow, B.M. Scirica, E. Karwatowska-Prokopczuk, S.A. Murphy, A. Budaj, and S. Varshavsky Effects of ranolazine on recurrent cardiovascular events in patients with non-st-elevation acute coronary syndromes: the merlin-timi 36 randomized trial JAMA 297 2007 1775 1783 (Pubitemid 46658646)
142. J.L. Sendon, S. Lee, M.L. Cheng, and O. Ben-Yehuda Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the combination assessment of ranolazine in stable angina (CARISA) randomized trial Eur J Prev Cardiol 19 2012 952 959
143. H. Matsumura, A. Hara, H. Hashizume, K. Maruyama, and Y. Abiko Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate Jpn J Pharmacol 77 1998 31 39 (Pubitemid 28263988)
144. O. Zeitz, A.E. Maass, P. Van Nguyen, G. Hensmann, H. Kogler, and K. Moller Hydroxyl radical-induced acute diastolic dysfunction is due to calcium overload via reverse-mode Na(+)-Ca(2+) exchange Circ Res 90 2002 988 995 (Pubitemid 34633865)
145. J.H. Ma, A.T. Luo, and P.H. Zhang Effect of hydrogen peroxide on persistent sodium current in guinea pig ventricular myocytes Acta Pharmacol Sin 26 2005 828 834
146. Z. Zhao, N. Fefelova, M. Shanmugam, P. Bishara, G.J. Babu, and L.H. Xie Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling J Mol Cell Cardiol 50 2011 128 136
147. S. Sossalla, U. Maurer, H. Schotola, N. Hartmann, M. Didie, and W.H. Zimmermann Diastolic dysfunction and arrhythmias caused by overexpression of camkiidelta(c) can be reversed by inhibition of late Na(+) current Basic Res Cardiol 106 2011 263 272